Maravai LifeSciences (NASDAQ:MRVI) and OmniAb (NASDAQ:OABIW) Head to Head Contrast

OmniAb (NASDAQ:OABIW) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings.

Insider and Institutional Ownership

50.2% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares OmniAb and Maravai LifeSciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$28.94 million	N/A	N/A	N/A	N/A
Maravai LifeSciences	$185.74 million	9.13	-$130.77 million	($0.71)	-9.25

OmniAb has higher earnings, but lower revenue than Maravai LifeSciences.

Profitability

This table compares OmniAb and Maravai LifeSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OmniAb	N/A	N/A	N/A
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Analyst Ratings

This is a summary of current recommendations and price targets for OmniAb and Maravai LifeSciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	0	0	0	0	0.00
Maravai LifeSciences	2	0	3	0	2.20

Maravai LifeSciences has a consensus target price of $5.50, suggesting a potential downside of 16.29%. Given Maravai LifeSciences’ stronger consensus rating and higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than OmniAb.

Summary

Maravai LifeSciences beats OmniAb on 6 of the 9 factors compared between the two stocks.

About OmniAb

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.